Stronger caffeine warnings
This article was originally published in The Tan Sheet
Executive Summary
Connecticut Attorney General Richard Blumenthal says May 1 FDA and Novartis should strengthen warning labels on caffeine product NoDoz following the death of a 19-year-old male. Blumenthal urges stronger warning labels about the severe health consequences of overdosing and caffeine toxicity, saying the current warning labels for NoDoz and other pill forms of caffeine are inadequate. He also advises increasing the minimum age for buying NoDoz from 12 to 18. A study reported in January found many multi-ingredient supplements containing caffeine were most commonly tied to supplement-related adverse events (1"The Tan Sheet" Jan. 29, 2007, p. 3)...
You may also be interested in...
Multi-Ingredient Caffeine Products Easily Top Adverse Event List, Study Finds
The vast majority of adverse events that can be attributed with near certainty to a supplement involve weight-loss or energy-enhancing products, a study conducted by Christine Haller, M.D., finds
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.